Immutep disclosed that an independent data monitoring committee recommended stopping its phase III TACTI‑004 study of eftilagimod alfa (efti) in first‑line non‑small‑cell lung cancer for futility. The company said it will wind down the trial and is conducting a comprehensive data review; investors reacted with a near‑total loss of market value on the announcement. The decision follows earlier positive signals for efti in smaller studies and leaves Immutep facing urgent strategic choices about its pipeline and cash runway. Immutep CEO Marc Voigt acknowledged the company’s surprise and disappointment and said management will analyze the dataset to determine next steps. For the broader oncology field, the stop raises questions about LAG‑3 agonist strategies and highlights the risk of translating phase II signals into registrational success.